Zoe Ward1, Jack Stone1, Chrissy Bishop2, Viktor Ivakin3, Ksenia Eritsyan4, Anna Deryabina3, Andrea Low5, Javier Cepeda6, Sherrie L Kelly7, Robert Heimer8, Robert Cook2, Frederick L Altice9, Taylor Litz9, Assel Terlikbayeva10, Nabila El-Bassel8, Denis Havarkov11, Alena Fisenka11, Anelia Boshnakova2, Andrey Klepikov12, Tetiana Saliuk12, Tetiana Deshko12, Peter Vickerman13. 1. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. 2. Economist Intelligence Unit, London, UK. 3. ICAP at Columbia University, Mailman School of Public Health, Columbia University, Almaty, Kazakhstan. 4. Sociology Department, HSE University, St Petersburg, Russia. 5. ICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, NY, USA. 6. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 7. Burnet Institute, Melbourne, VIC, Australia. 8. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA. 9. Section of Infectious Diseases, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA. 10. Columbia University Global Health Research Center of Central Asia, Almaty, Kazakhstan. 11. Republican Scientific and Practical Center of Medical Technologies, Informatization, Management and Economics of Public Health, Minsk, Belarus. 12. Alliance for Public Health, Kyiv, Ukraine. 13. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Electronic address: peter.vickerman@bristol.ac.uk.
Abstract
BACKGROUND: HIV incidence is increasing in eastern Europe and central Asia, primarily driven by injecting drug use. Coverage of antiretroviral therapy (ART) and opioid agonist therapy are suboptimal, with many people who inject drugs (PWID) being incarcerated. We aimed to assess whether use of monies saved as a result of decriminalisation of drug use or possession to scale up ART and opioid agonist therapy could control HIV transmission among PWID in eastern Europe and central Asia. METHODS: A dynamic HIV transmission model among PWID incorporating incarceration, ART, and opioid agonist therapy was calibrated to Belarus, Kazakhstan, Kyrgyzstan, and St Petersburg (Russia). Country-specific costs for opioid agonist therapy, ART, and incarceration were collated or estimated. Compared with baseline, the model prospectively projected the life-years gained, incremental costs (2018 euros), and infections prevented over 2020-40 for three scenarios. The decriminalisation scenario removed incarceration resulting from drug use or possession for personal use, reducing incarceration among PWID by 24·8% in Belarus, Kazakhstan, and Kyrgyzstan and 46·4% in St Petersburg; the public health approach scenario used savings from decriminalisation to scale up ART and opioid agonist therapy; and the full scale-up scenario included the decriminalisation scenario plus investment of additional resources to scale up ART to the UNAIDS 90-90-90 target of 81% coverage and opioid agonist therapy to the WHO target of 40% coverage. The incremental cost-effectiveness ratios per life-year gained for each scenario were calculated and compared with country-specific gross domestic product per-capita willingness-to-pay thresholds. Costs and life-years gained were discounted 3% annually. FINDINGS: Current levels of incarceration, opioid agonist therapy, and ART were estimated to cost from €198 million (95% credibility interval 173-224) in Kyrgyzstan to €4129 million (3897-4358) in Kazakhstan over 2020-40; 74·8-95·8% of these total costs were incarceration costs. Decriminalisation resulted in cost savings (€38-773 million due to reduced prison costs; 16·9-26·1% reduction in overall costs) but modest life-years gained (745-1694). The public health approach was cost saving, allowing each setting to reach 81% ART coverage and 29·7-41·8% coverage of opioid agonist therapy, resulting in 17 768-148 464 life-years gained and 58·9-83·7% of infections prevented. Results were similar for the full scale-up scenario. INTERPRETATION: Cost savings from decriminalisation of drug use could greatly reduce HIV transmission through increased coverage of opioid agonist therapy and ART among PWID in eastern Europe and central Asia. FUNDING: Alliance for Public Health, US National Institute of Allergy and Infectious Diseases and National Institute for Drug Abuse, and Economist Intelligence Unit.
BACKGROUND: HIV incidence is increasing in eastern Europe and central Asia, primarily driven by injecting drug use. Coverage of antiretroviral therapy (ART) and opioid agonist therapy are suboptimal, with many people who inject drugs (PWID) being incarcerated. We aimed to assess whether use of monies saved as a result of decriminalisation of drug use or possession to scale up ART and opioid agonist therapy could control HIV transmission among PWID in eastern Europe and central Asia. METHODS: A dynamic HIV transmission model among PWID incorporating incarceration, ART, and opioid agonist therapy was calibrated to Belarus, Kazakhstan, Kyrgyzstan, and St Petersburg (Russia). Country-specific costs for opioid agonist therapy, ART, and incarceration were collated or estimated. Compared with baseline, the model prospectively projected the life-years gained, incremental costs (2018 euros), and infections prevented over 2020-40 for three scenarios. The decriminalisation scenario removed incarceration resulting from drug use or possession for personal use, reducing incarceration among PWID by 24·8% in Belarus, Kazakhstan, and Kyrgyzstan and 46·4% in St Petersburg; the public health approach scenario used savings from decriminalisation to scale up ART and opioid agonist therapy; and the full scale-up scenario included the decriminalisation scenario plus investment of additional resources to scale up ART to the UNAIDS 90-90-90 target of 81% coverage and opioid agonist therapy to the WHO target of 40% coverage. The incremental cost-effectiveness ratios per life-year gained for each scenario were calculated and compared with country-specific gross domestic product per-capita willingness-to-pay thresholds. Costs and life-years gained were discounted 3% annually. FINDINGS: Current levels of incarceration, opioid agonist therapy, and ART were estimated to cost from €198 million (95% credibility interval 173-224) in Kyrgyzstan to €4129 million (3897-4358) in Kazakhstan over 2020-40; 74·8-95·8% of these total costs were incarceration costs. Decriminalisation resulted in cost savings (€38-773 million due to reduced prison costs; 16·9-26·1% reduction in overall costs) but modest life-years gained (745-1694). The public health approach was cost saving, allowing each setting to reach 81% ART coverage and 29·7-41·8% coverage of opioid agonist therapy, resulting in 17 768-148 464 life-years gained and 58·9-83·7% of infections prevented. Results were similar for the full scale-up scenario. INTERPRETATION: Cost savings from decriminalisation of drug use could greatly reduce HIV transmission through increased coverage of opioid agonist therapy and ART among PWID in eastern Europe and central Asia. FUNDING: Alliance for Public Health, US National Institute of Allergy and Infectious Diseases and National Institute for Drug Abuse, and Economist Intelligence Unit.
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Pieter Baker; Leo Beletsky; Liliana Avalos; Christopher Venegas; Carlos Rivera; Steffanie A Strathdee; Javier Cepeda Journal: Epidemiol Rev Date: 2020-11-13 Impact factor: 6.222
Authors: Harriet L Mills; Edward White; Caroline Colijn; Peter Vickerman; Robert Heimer Journal: Drug Alcohol Depend Date: 2013-05-18 Impact factor: 4.492
Authors: Frederick L Altice; Lyuba Azbel; Jack Stone; Ellen Brooks-Pollock; Pavlo Smyrnov; Sergii Dvoriak; Faye S Taxman; Nabila El-Bassel; Natasha K Martin; Robert Booth; Heino Stöver; Kate Dolan; Peter Vickerman Journal: Lancet Date: 2016-07-14 Impact factor: 79.321
Authors: Louisa Degenhardt; Amy Peacock; Samantha Colledge; Janni Leung; Jason Grebely; Peter Vickerman; Jack Stone; Evan B Cunningham; Adam Trickey; Kostyantyn Dumchev; Michael Lynskey; Paul Griffiths; Richard P Mattick; Matthew Hickman; Sarah Larney Journal: Lancet Glob Health Date: 2017-10-23 Impact factor: 26.763
Authors: Jack Stone; Hannah Fraser; Aaron G Lim; Josephine G Walker; Zoe Ward; Louis MacGregor; Adam Trickey; Sam Abbott; Steffanie A Strathdee; Daniela Abramovitz; Lisa Maher; Jenny Iversen; Julie Bruneau; Geng Zang; Richard S Garfein; Yung-Fen Yen; Tasnim Azim; Shruti H Mehta; Michael-John Milloy; Margaret E Hellard; Rachel Sacks-Davis; Paul M Dietze; Campbell Aitken; Malvina Aladashvili; Tengiz Tsertsvadze; Viktor Mravčík; Michel Alary; Elise Roy; Pavlo Smyrnov; Yana Sazonova; April M Young; Jennifer R Havens; Vivian D Hope; Monica Desai; Ellen Heinsbroek; Sharon J Hutchinson; Norah E Palmateer; Andrew McAuley; Lucy Platt; Natasha K Martin; Frederick L Altice; Matthew Hickman; Peter Vickerman Journal: Lancet Infect Dis Date: 2018-10-29 Impact factor: 71.421
Authors: Anna Meteliuk; Samy J Galvez de Leon; Lynn M Madden; Iryna Pykalo; Tatiana Fomenko; Myroslava Filippovych; Scott O Farnum; Sergii Dvoryak; Zahedul M Islam; Frederick L Altice Journal: J Subst Abuse Treat Date: 2020-10-10
Authors: Roman Ivasiy; Lynn M Madden; Scott O Farnum; Natalia Shumskaya; Samy J Galvez de Leon; Daniel J Bromberg; Ainura Kurmanalieva; Aibek Duishenaliev; Ruslan Tokubaev; Frederick L Altice Journal: Drug Alcohol Depend Rep Date: 2022-07-19
Authors: Jack Stone; Adelina Artenie; Matthew Hickman; Natasha K Martin; Louisa Degenhardt; Hannah Fraser; Peter Vickerman Journal: Lancet Public Health Date: 2022-01-07
Authors: Adrian Farid Elzarki; Seshagiri Rao Nandula; Hassan Awal; Gary L Simon; Sabyasachi Sen Journal: Stem Cell Res Ther Date: 2022-03-07 Impact factor: 6.832
Authors: Joseph G Rosen; Kristin E Schneider; Sean T Allen; Miles Morris; Glenna J Urquhart; Saba Rouhani; Susan G Sherman Journal: Harm Reduct J Date: 2022-10-15